The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
-
Published:2023-10-07
Issue:6
Volume:30
Page:872-884
-
ISSN:1340-6868
-
Container-title:Breast Cancer
-
language:en
-
Short-container-title:Breast Cancer
Author:
Terada Mitsuo, Ito Aki, Kikawa Yuichiro, Koizumi Kei, Naito Yoichi, Shimoi Tatsunori, Ishihara Mikiya, Yamanaka Takashi, Ozaki Yukinori, Hara Fumikata, Nakamura Rikiya, Hattori Masaya, Miyashita Minoru, Kondo Naoto, Yoshinami Tetsuhiro, Takada Masahiro, Matsumoto Koji, Narui Kazukata, Sasada Shinsuke, Iwamoto Takayuki, Hosoda Mitsuchika, Takano Yuko, Oba Takaaki, Sakai Hitomi, Murakami Akari, Higuchi Toru, Tsuchida Junko, Tanabe Yuko, Shigechi Tomoko, Tokuda Emi, Harao Michiko, Kashiwagi Shinichiro, Mase Junichi, Watanabe Junichiro, Nagai Shigenori E.ORCID, Yamauchi Chikako, Yamamoto Yutaka, Iwata Hiroji, Saji Shigehira, Toyama Tatsuya
Abstract
AbstractThe Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer were updated to the 2022 edition through a process started in 2018. The updated guidelines consist of 12 background questions (BQs), 33 clinical questions (CQs), and 20 future research questions (FRQs). Multiple outcomes including efficacy and safety were selected in each CQ, and then quantitative and qualitative systematic reviews were conducted to determine the strength of evidence and strength of recommendation, which was finally determined through a voting process among designated committee members. Here, we describe eight selected CQs as important updates from the previous guidelines, including novel practice-changing updates, and recommendations based on evidence that has emerged specifically from Japanese clinical trials.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference43 articles.
1. Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:322–31. 2. Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:4–8. 3. Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, et al. The Japanese Breast Cancer Society Clinical Practice Guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:9–16. 4. Uematsu T, Nakashima K, Kikuchi M, Kubota K, Suzuki A, Nakano S, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for breast cancer screening and diagnosis, 2018 Edition. Breast Cancer. 2020;27:17–24. 5. Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:74–84.
|
|